The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels
Open accessAbstract
Recently, cationic liposomes have been shown to preferentially target the angiogenic endothelium of tumors. It was the aim of our study to investigate the influence of liposomal surface charge on the uptake and kinetics of liposomes into solid tumors and tumor vasculature. Experiments were performed in the amelanotic hamster melanoma A‐Mel‐3 growing in the dorsal skinfold chamber preparation of male Syrian golden hamsters. Fluorescently labeled liposomes with different surface charge were prepared. Accumulation of i.v. injected liposomes was assessed by quantitative intravital fluorescence microscopy of tumor and surrounding host tissue. The histological distribution of liposomes was analyzed by double‐fluorescence microscopy 20 min after application of fluorescently labeled lectin as a vascular marker. After i.v. application of anionic and neutral liposomes, we observed an almost homogeneous distribution of liposome‐induced fluorescence throughout the chamber preparation without specific targeting to tumor tissue. In contrast, cationic liposomes exhibited a significantly enhanced accumulation in tumor tissue and tumor vasculature up to 3‐fold compared to surrounding tissue (p<0.05). The histological distribution of neutral and anionic liposomes revealed extravasation 20 min after i.v. injection, while cationic liposomes displayed a highly selective accumulation on the vascular endothelium. In conclusion, cationic liposomes exhibited a preferential uptake in angiogenic tumor vessels and therefore may provide an efficient tool for the selective delivery of diagnostic or therapeutic agents to angiogenic blood vessels of solid tumors. On the other hand, anionic and neutral liposomes may be used as carriers of drugs to the extravascular compartment of tumors due to their extravasation. © 2003 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dvorak, H. F., Brown, L. F., Detmar, M. J., & Dvořàk, A. M. (1995) · Europe PMC (PubMed Central) · Cited by 3,115
Barriers to Drug Delivery in Solid Tumors
Jain, R. K. (1994) · Scientific American · doi:10.1038/scientificamerican0794-58 · Cited by 1,069
Yuan, F., Leunig, M., Huang, S. K., Berk, D. A., Papahadjopoulos, D., & Jain, R. K. (1994) · PubMed · Cited by 908
Delivery of molecular and cellular medicine to solid tumors
Jain, R. K. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.011 · Cited by 774
Vink, H., & Duling, B. R. (1996) · Circulation Research · doi:10.1161/01.res.79.3.581 · Cited by 615
Pharmacokinetics of stealth versus conventional liposomes: effect of dose
Allen, T. M., & Hansen, C. (1991) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(91)90201-i · Cited by 579
Jain, R. K. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00131-9 · Cited by 529
Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice.
Thurston, G., McLean, J. W., Rizen, M., Baluk, P., Haskell, A., Murphy, T. J., Hanahan, D., & McDonald, D. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci965 · Cited by 423
Clinical Pharmacokinetics of Doxorubicin
Speth, P. A. J., van Hoesel, Q. G. C. M., & Haanen, C. (1988) · Clinical Pharmacokinetics · doi:10.2165/00003088-198815010-00002 · Cited by 420
Technical report—a new chamber technique for microvascular studies in unanesthetized hamsters
Endrich, B., Asaishi, K., Götz, A., & Meßmer, K. (1980) · Research in Experimental Medicine · doi:10.1007/bf01851841 · Cited by 405
Cited by
Delivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180
Bertrand, N., Wu, J., Xu, X., Kamaly, N., & Farokhzad, O. C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.009 · Cited by 2,824
Liposomes as nanomedical devices
Bozzuto, G., & Molinari, A. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s68861 · Cited by 2,261
Active targeting schemes for nanoparticle systems in cancer therapeutics
Byrne, J. D., Betancourt, T., & Brannon-Peppas, L. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.08.005 · Cited by 1,731
Liposome composition in drug delivery design, synthesis, characterization, and clinical application
Large, D. E., Abdelmessih, R. G., Fink, E. A., & Auguste, D. T. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113851 · Cited by 877
Strategies for advancing cancer nanomedicine
Chauhan, V. P., & Jain, R. K. (2013) · Nature Materials · doi:10.1038/nmat3792 · Cited by 812
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come
Yingchoncharoen, P., Kalinowski, D. S., & Richardson, D. R. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.012070 · Cited by 744
Current trends and challenges in cancer management and therapy using designer nanomaterials
Navya, P. N., Kaphle, A., Srinivas, S. P., Bhargava, S. K., Rotello, V. M., & Daima, H. K. (2019) · Nano Convergence · doi:10.1186/s40580-019-0193-2 · Cited by 672
Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment
Subhan, M. A., Yalamarty, S. S. K., Filipczak, N., Parveen, F., & Torchilin, V. P. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11060571 · Cited by 623
Delivery of Molecular and Nanoscale Medicine to Tumors: Transport Barriers and Strategies
Chauhan, V. P., Stylianopoulos, T., Boucher, Y., & Jain, R. K. (2011) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-061010-114300 · Cited by 597
Stylianopoulos, T., Munn, L. L., & Jain, R. K. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2018.02.005 · Cited by 563
Zeta potential: a case study of cationic, anionic, and neutral liposomes
Smith, M. C., Crist, R. M., Clogston, J. D., & McNeil, S. E. (2017) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-017-0527-z · Cited by 479
Polymeric nanoparticles for targeted treatment in oncology: current insights
Joshi, M. D., Patravale, V., & Prabhu, R. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s56932 · Cited by 438
The acidic tumor microenvironment: a target for smart cancer nano-theranostics
Feng, L., Dong, Z., Tao, D., Zhang, Y., & Liu, Z. (2018) · National Science Review · doi:10.1093/nsr/nwx062 · Cited by 426
van der Koog, L., Gandek, T. B., & Nagelkerke, A. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202100639 · Cited by 418
A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium
Santel, A., Aleku, M., Keil, O., Endruschat, J., Esche, V, Fisch, G., Dames, S., Löffler, K., Fechtner, M., Arnold, W., et al. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302777 · Cited by 368
Masarudin, M. J., Cutts, S. M., Evison, B. J., Phillips, D. R., & Pigram, P. J. (2015) · Nanotechnology, Science and Applications · doi:10.2147/nsa.s91785 · Cited by 342
Strategies to improve the EPR effect: A mechanistic perspective and clinical translation
Ikeda-Imafuku, M., Wang, L. L.-W., Rodrigues, D., Shaha, S., Zhao, Z., & Mitragotri, S. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.043 · Cited by 330
Resveratrol nanoformulations: Challenges and opportunities
Summerlin, N., Soo, E., Thakur, S., Qu, Z., Jambhrunkar, S., & Popat, A. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.01.003 · Cited by 316
Understanding and exploiting nanoparticles' intimacy with the blood vessel and blood
Setyawati, M. I., Tay, C. Y., Docter, D., Stauber, R. H., & Leong, D. T. (2015) · Chemical Society Reviews · doi:10.1039/c5cs00499c · Cited by 308
Surface charge critically affects tumor penetration and therapeutic efficacy of cancer nanomedicines
Wang, H.-X., Zuo, Z.-Q., Du, J.-Z., Wang, Y.-C., Sun, R., Cao, Z.-T., Ye, X.-D., Wang, J.-L., Leong, K. W., & Wang, J. (2016) · Nano Today · doi:10.1016/j.nantod.2016.04.008 · Cited by 285
Design considerations for nanotherapeutics in oncology
Stylianopoulos, T., & Jain, R. K. (2015) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.07.015 · Cited by 280
Iodinated blood pool contrast media for preclinical X-ray imaging applications – A review
Hallouard, F., Anton, N., Choquet, P., Constantinesco, A., & Vandamme, T. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.04.066 · Cited by 265
Macrophages inhibit neovascularization in a murine model of age-related macular degeneration
Apte, R. S., Richter, J., Herndon, J., & Ferguson, T. A. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030310 · Cited by 249
Optical imaging in drug discovery and diagnostic applications
LICHA, K., & OLBRICH, C. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2005.01.021 · Cited by 263
Liposomes in Cancer Therapy: How Did We Start and Where Are We Now
Fulton, M. D., & Najahi-Missaoui, W. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076615 · Cited by 258
Liu, Y., Crowe, W. N., Wang, L., Lu, Y., Petty, W. J., Habib, A. A., & Zhao, D. (2019) · Nature Communications · doi:10.1038/s41467-019-13094-5 · Cited by 254
Enhancing tumor penetration of nanomedicines
Sun, Q., Ojha, T., Kiessling, F., Lammers, T., & Shi, Y. (2017) · Biomacromolecules · doi:10.1021/acs.biomac.7b00068 · Cited by 198
Binding and interstitial penetration of liposomes within avascular tumor spheroids
Kostarelos, K., Emfietzoglou, D., Papakostas, A., Yang, W., Ballangrud, Å., & Sgouros, G. (2004) · International Journal of Cancer · doi:10.1002/ijc.20457 · Cited by 127
Metadata
- Authors
- Krasnici, S., Werner, A., Eichhorn, M. E., Schmitt‐Sody, M., Pahernik, S. A., Sauer, B., Schulze, B., Teifel, M., Michaelis, U., Naujoks, K., & Dellian, M.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2003-03-25
- Volume
- 105
- Issue
- 4
- Pages
- 561-567
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2040443361
- Cited by
- 313
- References
- 25
- FWCI
- 6.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.